Loading...
•
Jun 30, 2020
Wave Life Sciences Q2 2020 Earnings Report
Reported financial results for the second quarter ended June 30, 2020 and provided a business update.
Key Takeaways
Wave Life Sciences reported a net loss of $40.5 million in the second quarter of 2020. The company's cash and cash equivalents totaled $94.1 million as of June 30, 2020. They anticipate funding operating and capital expenditure requirements into the fourth quarter of 2021.
PRECISION-HD1 and PRECISION-HD2 trials data expected in 1Q 2021, including 32 mg dose cohorts.
C9orf72 and SNP3 clinical trial applications on track to be submitted in 4Q 2020.
ADAR editing advancing with additional in vivo data expected at upcoming Analyst & Investor Research Webcast.
Wave to host investor conference call and webcast at 8:30 a.m. ET today.
Forward Guidance
Wave expects that its existing cash and cash equivalents, together with expected and committed cash from its existing collaboration will enable the company to fund its operating and capital expenditure requirements into the fourth quarter of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...